Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells
- PMID: 20083663
- DOI: 10.4049/jimmunol.0902437
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells
Abstract
Membrane-bound IgE (mIgE) is part of the IgE-BCR and is essential for generating isotype-specific IgE responses. On mIgE(+) B cells, the membrane-bound epsilon-chain (mepsilon) exists predominantly in the long isoform, mepsilon(L), containing an extra 52 aa CepsilonmX domain between CH4 and the C-terminal membrane-anchoring segment; the short isoform of mepsilon, mepsilon(S), exists in minor proportions. CepsilonmX thus provides an attractive site for immunologic targeting of mIgE(+) B cells. In this study, we show that nine newly prepared CepsilonmX-specific mAbs, as well as the previously reported a20, bound to mIgE.Fc(L)-expressing CHO cells, while only 4B12 and 26H2 bound to mIgE.Fc(L)-expressing B cell line Ramos cells. The mAb 4B12 bound to the N-terminal part, 26H2 the middle part, and all others the C-terminal part of CepsilonmX. Expression of Igalpha and Igbeta on the mIgE.Fc(L)-CHO cells reduces the binding of a20 to CepsilonmX as compared with that of 4B12 and 26H2. The chimeric mAbs c4B12 and c26H2, when cross-linked by secondary antibodies, lysed mIgE.Fc(L)-Ramos cells by apoptosis through a BCR-dependent caspase pathway. Using PBMCs as the source of effector cells, c4B12 and c26H2 demonstrated Ab-dependent cellular cytotoxicity toward mIgE.Fc(L)-Ramos cells in a dose-dependent fashion. In cultures of PBMCs from atopic dermatitis patients, c4B12 and c26H2 inhibited the synthesis of IgE driven by anti-CD40 and IL-4. These results suggest that 4B12 and 26H2 and an immunogen using the peptide segments recognized by these mAbs are potentially useful for targeting mIgE(+) B cells to control IgE production.
Similar articles
-
Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells.Int Arch Allergy Immunol. 2002 Aug;128(4):315-24. doi: 10.1159/000063860. Int Arch Allergy Immunol. 2002. PMID: 12218370
-
Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells.Mol Immunol. 2012 Oct;52(3-4):279-88. doi: 10.1016/j.molimm.2012.06.004. Epub 2012 Jun 29. Mol Immunol. 2012. PMID: 22750228
-
CɛmX peptide-carrying HBcAg virus-like particles induced antibodies that down-regulate mIgE-B lymphocytes.Mol Immunol. 2012 Oct;52(3-4):190-9. doi: 10.1016/j.molimm.2012.05.015. Epub 2012 Jun 15. Mol Immunol. 2012. PMID: 22706073
-
Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.Pediatr Allergy Immunol. 2016 Aug;27(5):446-51. doi: 10.1111/pai.12584. Epub 2016 May 18. Pediatr Allergy Immunol. 2016. PMID: 27090058 Review.
-
Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E.Allergy Asthma Proc. 2006 Mar-Apr;27(2 Suppl 1):S7-14. Allergy Asthma Proc. 2006. PMID: 16722326 Review.
Cited by
-
Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells.Int J Mol Sci. 2023 Oct 8;24(19):14997. doi: 10.3390/ijms241914997. Int J Mol Sci. 2023. PMID: 37834445 Free PMC article.
-
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.J Clin Invest. 2022 Aug 1;132(15):e157765. doi: 10.1172/JCI157765. J Clin Invest. 2022. PMID: 35912861 Free PMC article.
-
Past, present, and future of anti-IgE biologics.Allergy. 2020 Oct;75(10):2491-2502. doi: 10.1111/all.14308. Epub 2020 Apr 21. Allergy. 2020. PMID: 32249957 Free PMC article. Review.
-
Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.Sci Rep. 2018 Aug 1;8(1):11548. doi: 10.1038/s41598-018-29664-4. Sci Rep. 2018. PMID: 30069035 Free PMC article.
-
Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells.Clin Transl Allergy. 2018 Jul 18;8:27. doi: 10.1186/s13601-018-0213-z. eCollection 2018. Clin Transl Allergy. 2018. PMID: 30026908 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
